In a recent in vivo study [31], 18F-MK6240 binding patterns in target regions of people with AD were consistent with neuropathological neurofibrillary Tau staging with minimal off-target binding, suggesting that this second-generation Tau tracer has promise to effectively monitor Tau deposition in people with DS-AD. This evidence concerns the gene MAPT and Alzheimer disease.